

Attorney Docket No.: 5455.210-US

PATENT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Widner et al.

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: April 12, 2001

Examiner: To Be Assigned

Confirmation No: To Be Assigned

For: Methods For Producing A Polypeptide In A Bacillus Cell

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)**

**Commissioner for Patents  
Washington, DC 20231**

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references was filed in US application no. **09/256,377** filed **February 26, 1999**, the benefit of which is claimed under 35 USC 120.

The references are as follows:


1. WO 94/25612
2. Agaisse et al., Molecular Microbiology, 13(1), pp. 97-107 (1994)
3. Hue et al., Journal of Bacteriology, Vol. 177, No. 12, pp. 3465-3471 (1995)
4. Ichikawa et al., FEMS Microbiology Letters, 111, pp. 219-224, (1993)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the references.

The information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: April 12, 2001



Robert L. Starnes, Reg. No. 41,324  
Novozymes Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100

FORM PTO-1449  
(Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. **5455.210-US**

Serial No. **To Be Assigned**

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Widner et al.**


Filing Date **April 12, 2001**

Group To Be Assigned

## U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		WO 94/25612	11/10/94	PCT			

11000 U.S. PTO  
09/834271



## FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
--	--

[illegible]

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.